Pancreatic Cancer Research

ResearcherHarbin Medical UniversityActive in the last 2 years

Bei Sun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6688-2294; OpenAlex author ID A5055896550, A5140827344. Sources: OpenAlex.

Their work

Papers
34 (first author 2, last author 15)
Trials
0
Grants
0
Labs led
1
Collaborators
95
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: none · 2014: 2 papers · 2015: 1 paper · 2016: 8 papers · 2017: 1 paper · 2018: 3 papers · 2019: 2 papers · 2020: 3 papers · 2021: 1 paper · 2022: 3 papers · 2023: 2 papers · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 34

  1. "Alkaline-Hammer Strategy" Breaks Acidic and Stromal Barriers to Induce Alkaliptosis and Enhance Immunotherapy in Pancreatic Cancer. Co-author DOI 10.1002/anie.8734845↗
  2. RNF187 neddylation in pancreatic cancer activates malignancy via IQGAP1-dependent actin cytoskeleton rearrangement. Co-author DOI 10.1038/s41388-025-03639-y↗
  3. LncRNA CCAT1 participates in pancreatic ductal adenocarcinoma progression by forming a positive feedback loop with c-Myc. Last author DOI 10.1093/carcin/bgad076↗
  4. Caprin-1 influences autophagy-induced tumor growth and immune modulation in pancreatic cancer. Co-author DOI 10.1186/s12967-023-04693-4↗
  5. The Prognostic and Immune Significance of CILP2 in Pan-Cancer and Its Relationship with the Progression of Pancreatic Cancer. Co-author DOI 10.3390/cancers15245842↗
  6. Diabetic Ferroptosis and Pancreatic Cancer: Foe or Friend? Co-author DOI 10.1089/ars.2022.0101↗
  7. Positive feedback regulation of lncRNA TPT1-AS1 and ITGB3 promotes cell growth and metastasis in pancreatic cancer. Co-author DOI 10.1111/cas.15388↗
  8. Alcohol-induced C/EBP β-driven KIAA1429 decreases oxidative stress and promotes pancreatic cancer growth and metastasis via the m6A/YTHDF2/SLC43A2 pathway Co-author DOI 10.21203/rs.3.rs-1721317/v1↗
  9. Integrating Genetic and Transcriptomic Data to Reveal Pathogenesis and Prognostic Markers of Pancreatic Adenocarcinoma. Co-author DOI 10.3389/fgene.2021.747270↗
  10. Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis. Co-author DOI 10.1016/j.canlet.2020.02.039↗
  11. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study. Co-author DOI 10.1016/j.ebiom.2020.102767↗
  12. Small Molecule Inhibitor C188-9 Synergistically Enhances the Demethylated Activity of Low-Dose 5-Aza-2'-Deoxycytidine Against Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.00612↗
  13. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1. Last author DOI 10.1186/s13046-019-1278-9↗
  14. Overexpression of KLF5 is associated with poor survival and G1/S progression in pancreatic cancer. Last author DOI 10.18632/aging.102096↗
  15. Crucial microRNAs and genes in metformin's anti-pancreatic cancer effect explored by microRNA-mRNA integrated analysis. Last author DOI 10.1007/s10637-017-0508-2↗
  16. MiR-361-3p regulates ERK1/2-induced EMT via DUSP2 mRNA degradation in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41419-018-0839-8↗
  17. Recent advances in research on aspartate β-hydroxylase (ASPH) in pancreatic cancer: A brief update. Co-author DOI 10.17305/bjbms.2018.3539↗
  18. Silencing IGFBP-2 decreases pancreatic cancer metastasis and enhances chemotherapeutic sensitivity. Last author DOI 10.18632/oncotarget.18669↗
  19. Hyperoside induces apoptosis and inhibits growth in pancreatic cancer via Bcl-2 family and NF-κB signaling pathway both in vitro and in vivo. Last author DOI 10.1007/s13277-015-4552-2↗
  20. Analysis of 300 consecutive cases of pancreatic adenocarcinoma in a single-center in China. Co-author DOI 10.1016/s1499-3872(16)60066-8↗
  21. Plasma miRNAs Effectively Distinguish Patients With Pancreatic Cancer From Controls: A Multicenter Study. Co-author DOI 10.1097/sla.0000000000001345↗
  22. Long Noncoding RNA MALAT1 Promotes Aggressive Pancreatic Cancer Proliferation and Metastasis via the Stimulation of Autophagy. Last author DOI 10.1158/1535-7163.mct-16-0008↗
  23. Dihydroartemisinin suppresses pancreatic cancer cells via a microRNA-mRNA regulatory network. Last author DOI 10.18632/oncotarget.11517↗
  24. Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer. Last author DOI 10.18632/oncotarget.12365↗
  25. Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study. Co-author DOI 10.18632/oncotarget.9491↗
  26. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreati… Co-author DOI 10.3892/ijo.2015.3316↗
  27. Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus … Co-author DOI 10.3892/ijo.2015.3128↗
  28. Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway. Last author DOI 10.1016/j.bcp.2014.01.041↗
  29. The activation of c-Jun NH₂-terminal kinase is required for dihydroartemisinin-induced autophagy in pancreatic cancer cells. Last author DOI 10.1186/1756-9966-33-8↗
  30. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both… Last author DOI 10.1007/s00432-012-1152-z↗
  31. Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5. Last author DOI 10.1371/journal.pone.0037222↗
  32. Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells. Last author DOI 10.1371/journal.pone.0043826↗
  33. Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway. First author DOI 10.1007/s00280-011-1643-7↗
  34. Nuclear factor-κB-dependent epithelial to mesenchymal transition induced by HIF-1α activation in pancreatic cancer cells under hypoxic conditions. First author DOI 10.1371/journal.pone.0023752↗

Closest collaborators

The 25 strongest of 95 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongwei Wang · 15 shared papers, 2011–2024 · strength 1.31
  2. Rui Kong · 16 shared papers, 2011–2023 · strength 1.13
  3. Yilong Li · 11 shared papers, 2014–2022 · strength 0.92
  4. Hongze Chen · 7 shared papers, 2016–2026 · strength 0.85
  5. Shangha Pan · 14 shared papers, 2011–2022 · strength 0.77
  6. Chundong Cheng · 4 shared papers, 2019–2026 · strength 0.75
  7. Jisheng Hu · 7 shared papers, 2017–2023 · strength 0.70
  8. Xuewei Bai · 7 shared papers, 2011–2026 · strength 0.68
  9. Gang Wang · 6 shared papers, 2016–2023 · strength 0.68
  10. Danxi Liu · 3 shared papers, 2022–2024 · strength 0.56
  11. Zonglin Liu · 3 shared papers, 2022–2024 · strength 0.56
  12. Zhongjie Zhao · 5 shared papers, 2016–2023 · strength 0.53
  13. Le Li · 6 shared papers, 2016–2022 · strength 0.53
  14. Wenbo Yang · 2 shared papers, 2023–2026 · strength 0.43
  15. Le Li · 4 shared papers, 2017–2022 · strength 0.43
  16. Le Li · 3 shared papers, 2016–2023 · strength 0.35
  17. Chengxiao Yang · 1 shared paper, 2026 · strength 0.28
  18. Xinyuan Liu · 1 shared paper, 2026 · strength 0.28
  19. Wei Liu · 1 shared paper, 2026 · strength 0.24
  20. Xinlong Wang · 1 shared paper, 2026 · strength 0.24
  21. Ping'an Ma · 1 shared paper, 2026 · strength 0.24
  22. Guanqun Li · 2 shared papers, 2018–2023 · strength 0.23
  23. Hongchi Jiang · 6 shared papers, 2011–2016 · strength 0.21
  24. Taiping Zhang · 3 shared papers, 2016–2020 · strength 0.20
  25. Lei You · 3 shared papers, 2016–2020 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.